March 8, 2024 · Form 4 insider transaction
Ellingson Rachel bought 11,264 shares of BioLife Solutions, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date.